<Date>

immunoSCAPE Investor Presentation DeckEnabling Immunotherapy

2

The leading partner in immunotherapy drug development

immunoSCAPE

Optimization of

immunotherapy pipeline

• Decrease clinical trial failure

• Prioritize combinations with

higher chance of efficacy

• Replenish pipeline

Biomarkers for identification of

treatment responders

Discover of novel therapeutic targets

Assessment of drug biological activity

Needs in immunotherapy drug

development

PartnersOrganizations developing immunotherapy

solutions in cancer, infectious and

autoimmune diseases

3

What is Cancer Immunotherapy?

• Immune attack is specific to cancer cells

• Fewer severe complications

• Protection could be for life

• Used in combination with chemotherapies

Checkpoint

inhibitors

T-Cell

therapies

Cancer

Vaccines

vs.

$-

$50.00

$100.00

$150.00

$200.00

$250.00

$300.00

Year 2018 Year 2023

$139.66

$259.60

Global immunotherapy drug market(Bil USD)

4

Rapid expansion of immunotherapy R&Ddrives growth in immune profiling

14.3% CAGR

Sources: IQVIA Institute, May 2018Research and Markets: Cancer Immunotherapy - Global Market Outlook (2017-2023)

More than 2,000 clinical trials in immunotherapy globally

Driving growth in immune profiling

cancer (immuno-oncology)

11%

cancer (other)38%

infectious (viral)

3%

infectious (other)

4%

autoimmune3%

other diseases

41%

On-going Phase I, II, III Clinical Trials

(as of Dec 2018; n=23,516)

source: ClinicalTrials.gov

5

immunoSCAPE Strengths and Differentiation

Mapping the landscape of immune

responses

Identifying targets that

killer T cells recognize on

tumor cells

DiseasedHealthy

Killer T cell

Tumor cell

After treatment

?

Broad profiling while simultaneously screening for large

number of specific T cell targets

1 2

Proteomic immune profiling, especially TCR specificity, phenotype, and function of T cells

Partnering to provide value to immunotherapy drug development

Blood or tissue

Sample Reagents Measurement Bio-infoClinical

insights

Tetramer

Antibody

Metal tag

Panel design

CyTOF Data analysis

Clinical questions customers want to address

1. Is a drug candidate more immunogenically active?

2. Is a patient likely to respond and/or actually responding to immunotherapy?

3. What is biological activity and mechanism of action, caused by a drug candidate?

These are critical to maximize the chance of clinical trial success and drug approval.

Reporting

7

Partnering with immunotherapy companies and academic institutions with its cutting-edge immune profiling technology

The immunoSCAPE story

2017 2019 2021 202220202018

✓ Proven core technology

✓ Publishing validation

✓ World leading customers

4X

✓ Partnering with drug development companies

✓ Scaling up - expand depth and breadth of technology

✓ Global expansion to broaden market reach

2023

USD$1.8MSGD$2.4M

USD$1.4MSGD$1.9M

signed(as of Q2)

Contracts Signed $ Projections $

USD$0.4MSGD$0.5M

3X

USD$2.9MSGD$3.9M

under discussion

• US Academic lab

• Clinical teams in

Singapore8

immunoSCAPE’s partnership has expanded across three different fields

Current Partners and Pipeline

Cancer

Funded by Gates Foundation

Autoimmune

diseases

Infectious

diseases

US Corp

Existing

Customers

US Biotech European

CorpEuropean

CorpPipeline

CustomersUS Corp

9

Financial Projections

✓ Forecasted revenue and operating profit in 2024 are SGD $63MM and SGD $21MM, respectively

✓ Higher investments in disruptive technologies enable:o Access to mid-tier customer segmentso Higher productivity, increased margins

10

A team with the scope of expertise to run a successful businessMeet the immunoSCAPE Team

Management

Mr Ng Choon Peng

Co-Founder / CEO

Previously in GSK, Country Manager J&J, CEO of LEO

Pharma Asia and CEO CrysBio, Snr Dir A*STAR;

extensive experience in business management and

marketing.

Dr Alessandra Nardin

Co-Founder / COO

Previously in IDM Biotech and SIgN, A*STAR; tumor

immunologist with experience in translational

immunology and business development.

Dr Michael Fehlings

Co-Founder / Director, Scientific Affairs

Previously in Newell’s lab in SIgN, in-depth and

hands-on expertise in mass cytometry and

multiplexing tetramer technology.

Advisors

Dr Evan Newell, Co-Founder / Scientific Advisor

Pioneered the use of mass cytometry for high-dimensional immune

profiling and translational T cell immunology in Stanford and A*STAR.

He is currently at Fred Hutch.

Dr Andreas Wallnoefer, Strategic Advisor

Previously Global Head of Clinical Research & Exploratory

Development in Roche, more recently at the University of Basel and

on the Board of several biotech companies.

Prof Soo Khee Chee, Strategic Advisor

Founding Director of National Cancer Centre Singapore and key

contributor in the establishment of Duke-NUS School of Medicine;

renowned cancer clinician critical in placing Singapore to the forefront

of translational medicine.

Jack Ball, Strategic Advisor

Previously held C-level positions in pharma and biotech. Served as

CCO of Accuri Cytometers. Consults and serves on the board of

several biotech companies.

Graeme R. Martin, Strategic Advisor

Previously the President/CEO of Takeda Ventures for 14 years.

Served as CTO at Telik, Inc., VP of CNS at Roche. Currently advises

and serves on the board of several startup biotech.